Probiotics cut severe gut disease and death risk in preterm infants, review finds

Preterm infants face a heightened risk of gut dysbiosis, a state marked by reduced microbial diversity, delayed colonization by beneficial commensals such as Bifidobacterium, and overgrowth of opportunistic pathogens. This disrupted microbial ecosystem is closely linked to life-threatening conditions including necrotizing enterocolitis (NEC), late-onset sepsis (LOS), and feeding intolerance, and has also been implicated in long-term neurodevelopmental and respiratory outcomes. A narrative review now synthesizes evidence from randomized controlled trials, observational studies, systematic reviews, and meta-analyses to assess how probiotic supplementation shapes the microbiota and clinical outcomes in this vulnerable population.

The review concludes that multi-strain probiotics reduce severe NEC and all-cause mortality. Specific multi-strain formulations containing well-defined Lactobacillus and Bifidobacterium strains were associated with significant reductions in the incidence of severe NEC, with risk ratios of 0.38 to 0.57, and in all-cause mortality, with a risk ratio of 0.69. Probiotics also consistently enhanced intestinal abundance of beneficial bacteria, modulated metabolic profiles, and reduced markers of intestinal inflammation. However, their effect on preventing LOS and on reducing colonization by multidrug-resistant organisms was less consistent across studies.

A central theme of the review is strain specificity: effects observed with one formulation cannot be extrapolated across products, and future trials should report full strain identity, dose, viability, and product composition. Emerging evidence suggests probiotics may influence immune cell development and the gut-brain axis, with possible implications for neurodevelopment and seizure prevention, but the review stresses that these findings remain preliminary and that neurodevelopmental benefit is unproven. Significant challenges persist, including heterogeneity in study designs, probiotic strains, and clinical protocols, safety concerns in extremely low-birth-weight infants, and methodological issues surrounding product quality and taxonomic identification.

On the question of practice, the authors conclude that routine universal use of probiotics in preterm infants is not justified by the current evidence, and that translation into standard care requires product-specific trials and regulatory-grade quality control. The findings position probiotics as a promising but not yet universally applicable intervention: certain defined multi-strain products show meaningful reductions in severe NEC and mortality, while benefits for sepsis prevention and long-term development await more rigorous, strain-resolved evidence.

Subject of Research: Probiotic modulation of gut microbiota and clinical outcomes in preterm infants

Article Title: Probiotic modulation of gut microbiota in preterm infants: a narrative review of clinical evidence, mechanisms, and translational gaps

Article References: Xie, D., Yuan, H., & Zhang, D. (2026). Probiotic modulation of gut microbiota in preterm infants: a narrative review of clinical evidence, mechanisms, and translational gaps. Frontiers in Microbiology, 17, Article 1945012. https://doi.org/10.3389/fmicb.2026.1945012

Image Credits: AI Generated

DOI: 10.3389/fmicb.2026.1945012

Keywords: probiotics, preterm infants, necrotizing enterocolitis, gut microbiota, late-onset sepsis, Bifidobacterium, Lactobacillus, dysbiosis, strain specificity, gut-brain axis, Probiotic, modulation